Medicus Pharma secures $8 million debenture financing for drug development

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Medicus Pharma secures $8 million debenture financing for drug development

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

September 18, 2025 7:30 AM EDT

The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~ $6 billion in potential market opportunity

PHILADELPHIA, PA / ACCESS Newswire / September 18, 2025 / Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and disruptive therapeutics assets, is pleased... More